Statistical considerations on a new design method for multiregional clinical trial: SGDDPHUANG Qin, WANG Jun, QU Rong-hua, CHEN Gang, YUAN Zhi-long721-724,744
The incentives and technical gaps faced by Chinese manufacturers producing chemical generic medicines to achieve the standards of WHO Medicines PrequalificationHUANG Bao-bin, Christina Forge-Wimmer, SUN Xin-sheng, XU Ming-zhe, BAI Dong-ting, WU Zhi-ang, WU Chun-fu725-729
Structural convergence and influencing factors of Chinese pharmaceutical industry regional layoutXU Huai-fu, WANG Xin730-736
Constructing pharmaceutical R&D cycle-based multi-directional risk management mechanismLI Zhang-ming, ZHU Wen-liang, LIU Lan-ru, ZHU Hong737-740
Discussion about the orphan drug pricing regulation system from the perspective of pricing and reimbursementCHANG Feng, SHANG Xiao-ting741-744
Requirement and evaluation of studies on using macroporus adsorption resin for further purification of extracts from Chinese herbal medicinesSONG Dan, ZHANG Yong-wen745-749
Protective effects of diammonium glycyrrhizinate on permeability increasing and chromosome breakage induced by triptolideDAN Mo, WEN Hai-ruo, WEN Nie, LIU Li, LI Zuo-gang750-754,770
Quality evaluation of agomelation orally disintegrating tablets with multi-particulate formZHOU Xiao-yun, ZHANG Hui, LI Zhi-ping, XIE Xiang-yang, YANG Yan-fang, MEI Xing-guo755-759,781
Preparation of high purity human coagulation factor Ⅷ using ion exchange chromatography刘晓, 韩国德, 李青, 郭广兆, 包正琦, 张金, 张安山, 何彦林760-764,799
Progress in research of neurokinin-1 receptor antagonists, new drugs for preventing and treating chemotherapy-induced nausea and vomitingSUN Xiu-bo, HE Yi-chen, LIU Lei765-770